Reshape Lifesciences Inc Net Income per Employee (RSLS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Reshape Lifesciences Inc  (NASDAQ: RSLS)
 

Reshape Lifesciences Inc Net Income per Employee

RSLS's Quarterly Results, Trends, Rankings, Statistics
Reshape Lifesciences Inc recorded a cumulative net loss of $-11 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 159 other companies achieving higher income per employee. While Reshape Lifesciences Inc's total ranking has deteriorated compared to the previous quarter from 2670 to 3484.


What is Income per Employee Ratio?






RSLS Net Income per Employee (Mar 31 2026)
I. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -596,490 -639,572 -249,889 -192,389 -396,111
RSLS's Total Ranking # 3484 # 2670 # 2317 # 2256 #
Seq. Net Income Change - - - - -


RSLS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 476
Overall Market # 3484

Net Income per Employee Statistics
High Average Low
$ -192,389 $ -1,985,411 $ -4,679,475
(Mar 31 2025)   (Dec 31 2018)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-30T14:56:47+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.